The material selection platform
Plastics & Elastomers
The material selection platform
Plastics & Elastomers
Product News

Lubrizol Highlighted Broad Range of TPU Products for Wound Care Devices & more at AAPS

Published on 2014-11-24. Author : SpecialChem

CLEVELAND -- The Lubrizol Corporation’s LifeSciences business, among the leading suppliers of advanced materials for the pharmaceutical and medical device industry, showcased its extensive range of material solutions for the pharmaceutical industry at the American Association of Pharmaceutical Scientists (AAPS) conference Nov. 2-6 at the San Diego Convention Center (booth 1817). The company highlighted its new pharmaceutical-grade Pathway™ thermoplastic polyurethane (TPU) excipients and its range of TPU products for wound care devices and treatments.

Lubrizol’s new Pathway TPU excipients provide a customizable, reliable, and innovative solution for both new drug development and life cycle management. “The expansion of new routes of administration for existing drug products is an important strategy that pharmaceutical companies can use to help maintain the success of their product franchises,” says Joey Glassco, global market manager for Lubrizol LifeSciences. “Pathway excipients are designed to help drug manufacturers achieve their goals of developing these novel, controlled release drug delivery products,” adds Glassco.

New Pathway excipients for non-biodegradable drug delivery systems such as vaginal rings and subcutaneous implants are more versatile compared to traditional materials used in these drug delivery applications. Pathway TPUs are manufactured under IPEC GMP guidelines for excipients and are ideal for combination products that can deliver a wide variety of drugs – both hydrophobic and hydrophilic - because the polymers can be chemically engineered to meet tough drug delivery challenges.

At AAPS, Lubrizol also featured its recently launched Pellethane® TPU products for wound care and medical device applications. New Pellethane TPU grades provide a high moisture vapor transmission rate (MVTR) for film wound care applications. TPU products such as Lubrizol’s Tecophilic™ and Pellethane grades are considered preferred polymers for these applications because of the materials’ biocompatibility, ability to absorb moisture, provide breathability and supply an adequate barrier to contaminants and microbes, while maintaining comfort for the patient.

Carbopol® carbomers as well as Tecophilic and Pellethane TPU can also be used in synthetic dressings. Applications include products such as hydrogels and woven or non-woven dressings. Hydrogels are used in tandem with a backing to absorb or provide moisture, provide cooling comfort sensations in a wound or to fill a void during healing.

Pellethane® is a registered trademark of The Lubrizol Corporation
Tecophilic™ is a trademark of The Lubrizol Corporation
Pathway™ is a trademark of The Lubrizol Corporation
Carbopol® is a registered trademark of The Lubrizol Corporation

The Lubrizol Corporation

The Lubrizol Corporation, a Berkshire Hathaway company, is a technology-driven global company that combines complex, specialty chemicals to optimize the quality, performance and value of customers’ products while reducing their environmental impact. It produces and supplies technologies to customers in the global transportation, industrial and consumer markets. These technologies include lubricant additives for engine oils, driveline and other transportation-related fluids, industrial lubricants, as well as additives for gasoline and diesel fuel. In addition, Lubrizol makes ingredients and additives for home care and personal care products and pharmaceuticals, and specialty materials, including plastics technology and performance coatings in the form of specialty resins and additives.

With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 7,500 employees worldwide. Revenues for 2013 were $6.4 billion.

Source: Lubrizol Corporation

Back to Top